MSD

News

Immutep mulls filings for LAG-3 drug after new readout

Shares in Immutep have leapt after the biotech reported phase 2b results showing that LAG-3 inhibitor eftilagimod alfa (efti) significantly boosted the efficacy of MSD’s Keytruda in patient

News

FDA turns down MSD, Daiichi Sankyo HER3 ADC for lung cancer

The FDA has said it cannot approve MSD and Daiichi Sankyo’s HER3-targeted antibody-drug conjugate (ADC) patritumab deruxtecan because of problems at a third-party manufacturer.

News

FDA says yes to MSD’s 21-valent adult pneumococcal jab

The rivalry between Pfizer and MSD in pneumococcal vaccines has dialled up a notch with the FDA approval of MSD’s new shot Capvaxive, the first to be aimed specifically at adults.

News

ASCO: Moderna may file melanoma vaccine on phase 2b data

New data from a phase 2b trial of Moderna and MSD’s neoantigen melanoma vaccine may be strong enough to consider filing for accelerated approval before a phase 3 programme

News

Update: MSD confirms $3bn takeover of EyeBio

MSD has confirmed a $3 billion takeover deal for ophthalmology biotech EyeBio and its drug candidate for diabetic macular oedema (DME) and neovascular age-related macular

News

AstraZeneca throws its hat into the oral PCSK9 ring

AstraZeneca has reported the first clinical data with its oral PCSK9 inhibitor AZD0780, which it hopes could offer an alternative to current injectable drugs used to lower

Immutep mulls filings for LAG-3 drug after new readout

FDA turns down MSD, Daiichi Sankyo HER3 ADC for lung cancer

FDA says yes to MSD’s 21-valent adult pneumococcal jab

ASCO: Moderna may file melanoma vaccine on phase 2b data

Update: MSD confirms $3bn takeover of EyeBio

AstraZeneca throws its hat into the oral PCSK9 ring

Repligen builds in cell therapy with $1.5bn BioLife takeover

Discover a new era of healthcare panel engagement: Grounded ...

MSD

Editor's Picks